Essex Bio-Technology (01061) has announced that on August 24, 2026, it allocated HK$90,600 to buy back 40,000 of its own shares.

This repurchase move reflects the company's ongoing capital management strategy, aimed at enhancing shareholder value through the reduction of outstanding shares in the market.

The transaction was executed on the open market, with the total expenditure for the buyback amounting to approximately HK$90,600.